Shan Hu Leads Contemporaneous Shift Toward Advanced Molecular Targets in Coronary Artery Disease Treatment.

Coronary Artery Disease Stays Global Killer

As of September 2026, coronary artery disease (CAD) continues to be the leading global cause of death despite the limitations of older pharmacological treatments.

A state-of-the-art review published in Cardiovascular Innovations and Applications (CVIA) highlights how novel lipid-lowering agents, anti-inflammatory therapies, and metabolic modulators are expanding clinical options.

Targeting Lipids and Vascular Inflammation

Traditional pharmacological interventions have historically struggled to fully mitigate the progression of CAD. Researchers led by Shan Hu, Zhen Guo, and Chenze Li have outlined a contemporary shift toward advanced molecular targets.

Deploying Anti-Inflammatory Therapies

Beyond lipid control, modern therapeutic pipelines focus heavily on vascular inflammation.

By deploying anti-inflammatory therapies that selectively target interleukin pathways, clinicians can address the inflammatory drivers of plaque vulnerability.

Genomic Profiling and AI Integration

The transition away from a generalized “one-size-fits-all” model relies heavily on genomic profiling and biomarker-based stratification.

Precision medicine frameworks allow clinicians to match specific CAD phenotypes with targeted pharmacological agents. Concurrently, artificial intelligence is streamlining drug discovery pipelines, helping researchers sift through vast biochemical datasets to identify promising new therapeutic targets with greater speed and accuracy.

Building a Defense Against Mortality

These translational breakthroughs mark a critical evolution in cardiovascular medicine.

By combining molecular target identification with computational acceleration, the medical research community is creating a stronger defense against the world's leading cause of death.